Mechanisms and emerging strategies for irinotecan-induced diarrhea

[1]  Kazumasa Kotake,et al.  Efficacy of Hangeshashinto in the Prevention of Chemotherapy-Induced Diarrhea: A Systematic Review and Meta-Analysis , 2023, Cureus.

[2]  Z. Chen,et al.  LBA61 HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC) , 2022, Annals of Oncology.

[3]  Jaw-Yuan Wang,et al.  Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous UGT1A1*28 polymorphism: a single-center case series , 2022, The Journal of international medical research.

[4]  F. Innocenti,et al.  Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs , 2022, Cancer science.

[5]  Yeh-long Chen,et al.  Inhibition of gut microbial β-glucuronidase effectively prevents carcinogen-induced microbial dysbiosis and intestinal tumorigenesis. , 2022, Pharmacological research.

[6]  F. Innocenti,et al.  All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide. , 2021, JCO oncology practice.

[7]  G. Abou-Alfa,et al.  Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. , 2021, The Lancet. Oncology.

[8]  A. Scott,et al.  Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy , 2021, Nature Nanotechnology.

[9]  Jaw-Yuan Wang,et al.  A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab , 2021, Oncology research.

[10]  M. Chamaillard,et al.  The role of the gut microbiome on radiation therapy efficacy and gastrointestinal complications: A systematic review. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  Lijun Shen,et al.  Multicenter, Randomized, Phase III Trial of Neoadjuvant Chemoradiation With Capecitabine and Irinotecan Guided by UGT1A1 Status in Patients With Locally Advanced Rectal Cancer , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Yue Shi,et al.  Identification of the bioactive components of Banxia Xiexin Decoction that protect against CPT-11-induced intestinal toxicity via UPLC-based spectrum-effect relationship analyses. , 2020, Journal of ethnopharmacology.

[13]  A. Rowland,et al.  Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping. , 2020, Pharmacology & therapeutics.

[14]  Zhiguang Sun,et al.  Rhein modulates host purine metabolism in intestine through gut microbiota and ameliorates experimental colitis , 2020, Theranostics.

[15]  Jaw-Yuan Wang,et al.  Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST). , 2020, European journal of cancer.

[16]  S. Servaes,et al.  Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Leah M Chase,et al.  Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. , 2020, JAMA network open.

[18]  Xin Wang,et al.  Ganciclovir reduces irinotecan-induced intestinal toxicity by inhibiting NLRP3 activation , 2019, Cancer Chemotherapy and Pharmacology.

[19]  Paul Awolade,et al.  Therapeutic significance of β-glucuronidase activity and its inhibitors: A review , 2019, European Journal of Medicinal Chemistry.

[20]  C. Bailly.  Irinotecan: 25 years of cancer treatment. , 2019, Pharmacological research.

[21]  O. Mir,et al.  Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. , 2019, Pharmacology & therapeutics.

[22]  G. Yi,et al.  A novel mechanism of irinotecan targeting MDM2 and Bcl-xL. , 2019, Biochemical and biophysical research communications.

[23]  Hong Ding,et al.  Herbal Medicines for Irinotecan-Induced Diarrhea , 2019, Front. Pharmacol..

[24]  A. Stringer,et al.  Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model , 2019, Cancer Chemotherapy and Pharmacology.

[25]  K. Higuchi,et al.  Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer , 2019, Gastric Cancer.

[26]  C. Tzeng,et al.  Pharmacological inhibition of bacterial &bgr;‐glucuronidase prevents irinotecan‐induced diarrhea without impairing its antitumor efficacy in vivo , 2019, Pharmacological research.

[27]  Yihan Wu,et al.  Traditional Chinese medicine Gegen Qinlian decoction ameliorates irinotecan chemotherapy-induced gut toxicity in mice. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[28]  A. Barnadas,et al.  Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype , 2018, British Journal of Cancer.

[29]  P. Bossi,et al.  Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  P. Lian,et al.  Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  M. Sanjurjo-Sáez,et al.  Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan , 2018, Pharmacological research.

[32]  Xue Zhang,et al.  Darunavir alleviates irinotecan‐induced intestinal toxicity in Vivo , 2018, European journal of pharmacology.

[33]  R. Scholten,et al.  Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer. , 2018, The Cochrane database of systematic reviews.

[34]  M. Delorenzi,et al.  Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. , 2018, European journal of cancer.

[35]  M. Redinbo,et al.  Gut Microbial β-Glucuronidase Inhibition via Catalytic Cycle Interception , 2018, ACS central science.

[36]  R. Mathijssen,et al.  Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics , 2018, Clinical Pharmacokinetics.

[37]  R. Tampé,et al.  Camptothecin and its analog SN‐38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE , 2017, Biochemical pharmacology.

[38]  M. Amri,et al.  Irinotecan chemotherapy-induced intestinal oxidative stress: Underlying causes of disturbed mucosal water and electrolyte transport. , 2017, Pathophysiology : the official journal of the International Society for Pathophysiology.

[39]  Le Liu,et al.  Metformin protects against intestinal barrier dysfunction via AMPKα1‐dependent inhibition of JNK signalling activation , 2017, Journal of cellular and molecular medicine.

[40]  M. Redinbo,et al.  An Atlas of β-Glucuronidases in the Human Intestinal Microbiome. , 2017, Structure.

[41]  R. Kalluri,et al.  An evolving function of DNA-containing exosomes in chemotherapy-induced immune response , 2017, Cell Research.

[42]  Min Huang,et al.  Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation , 2017, Cell Research.

[43]  L. Pan,et al.  Preventive Effects of a Chinese Herbal Formula, Shengjiang Xiexin Decoction, on Irinotecan-Induced Delayed-Onset Diarrhea in Rats , 2017, Evidence-based complementary and alternative medicine : eCAM.

[44]  J. Bornstein,et al.  Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments , 2016, Front. Pharmacol..

[45]  J. Bowen,et al.  TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced Diarrhea , 2016, Molecular Cancer Therapeutics.

[46]  D. Su,et al.  Propionate Ameliorates Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Reducing Inflammation and Oxidative Stress , 2016, Front. Pharmacol..

[47]  F. Innocenti,et al.  Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer , 2016, Clinical Cancer Research.

[48]  N. Zhou,et al.  UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer , 2016, Cancer Chemotherapy and Pharmacology.

[49]  Yan-Shen Shan,et al.  Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.

[50]  Si Ming Man,et al.  AIM2 inflammasome in infection, cancer, and autoimmunity: Role in DNA sensing, inflammation, and innate immunity , 2016, European journal of immunology.

[51]  Y. Zhuo,et al.  Doxycycline Protects Thymic Epithelial Cells from Mitomycin C-Mediated Apoptosis In Vitro via Trx2-NF-κB-Bcl-2/Bax Axis , 2016, Cellular Physiology and Biochemistry.

[52]  Qiang Xu,et al.  CPT-11 activates NLRP3 inflammasome through JNK and NF-κB signalings. , 2015, Toxicology and applied pharmacology.

[53]  P. Nighot,et al.  Lipopolysaccharide Regulation of Intestinal Tight Junction Permeability Is Mediated by TLR4 Signal Transduction Pathway Activation of FAK and MyD88 , 2015, The Journal of Immunology.

[54]  T. Cai,et al.  Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death , 2015, Nature.

[55]  L. Wagner.  Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? , 2015, Clinical Sarcoma Research.

[56]  J. Beniak,et al.  Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. , 2015, Complementary therapies in medicine.

[57]  J. Schuetz,et al.  Compartmentalized Accumulation of cAMP near Complexes of Multidrug Resistance Protein 4 (MRP4) and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Contributes to Drug-induced Diarrhea* , 2015, The Journal of Biological Chemistry.

[58]  R. Kim,et al.  OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy , 2015, British Journal of Cancer.

[59]  U. Nielsen,et al.  Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. , 2014, Cancer research.

[60]  Teruhiko Yoshida,et al.  Application of a Combination of a Knowledge-Based Algorithm and 2-Stage Screening to Hypothesis-Free Genomic Data on Irinotecan-Treated Patients for Identification of a Candidate Single Nucleotide Polymorphism Related to an Adverse Effect , 2014, PloS one.

[61]  Soma Das,et al.  Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Stephen T. C. Wong,et al.  Old Drug New Use—Amoxapine and Its Metabolites as Potent Bacterial β-Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity , 2014, Clinical Cancer Research.

[63]  Yang Zhang,et al.  IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21(WAF1) and p27(KIP1.). , 2014, Pharmacological research.

[64]  H. Takada,et al.  Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration , 2014, International Journal of Clinical Oncology.

[65]  D. McGuire,et al.  MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy , 2014, Cancer.

[66]  N. Al-Dasooqi,et al.  Irinotecan disrupts tight junction proteins within the gut , 2014, Cancer biology & therapy.

[67]  J. Sakamoto,et al.  Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations , 2014, Molecular Diagnosis & Therapy.

[68]  Ming Li,et al.  UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians , 2014, Cancer Chemotherapy and Pharmacology.

[69]  A. Schieber,et al.  The Role of Intestinal Microbiota in Development of Irinotecan Toxicity and in Toxicity Reduction through Dietary Fibres in Rats , 2014, PloS one.

[70]  M. Redinbo,et al.  Molecular Insights into Microbial β-Glucuronidase Inhibition to Abrogate CPT-11 Toxicity , 2013, Molecular Pharmacology.

[71]  A. Stringer.  Interaction between Host Cells and Microbes in Chemotherapy-Induced Mucositis , 2013, Nutrients.

[72]  E. Capoluongo,et al.  Gilbert and Crigler Najjar syndromes: an update of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene mutation database. , 2013, Blood cells, molecules & diseases.

[73]  Kazuyuki Inoue,et al.  Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. , 2013, The Tohoku journal of experimental medicine.

[74]  R. Danesi,et al.  Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. , 2011, Current drug metabolism.

[75]  M. Baiget,et al.  A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer , 2011, British Journal of Cancer.

[76]  Yiping Guo,et al.  Interleukin-1 receptor antagonist attenuates cyclophosphamide-induced mucositis in a murine model , 2011, Cancer Chemotherapy and Pharmacology.

[77]  John E. Scott,et al.  Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme , 2010, Science.

[78]  F. Innocenti,et al.  Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  E. Wiemer,et al.  A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan , 2010, Clinical Cancer Research.

[80]  A. Stringer,et al.  Irinotecan-induced mucositis is associated with changes in intestinal mucins , 2009, Cancer Chemotherapy and Pharmacology.

[81]  H. Friedman,et al.  Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma , 2009, Cancer Chemotherapy and Pharmacology.

[82]  S. Duncan,et al.  Distribution of beta-glucosidase and beta-glucuronidase activity and of beta-glucuronidase gene gus in human colonic bacteria. , 2008, FEMS microbiology ecology.

[83]  Richard A. Flavell,et al.  The Nalp3 inflammasome is essential for the development of silicosis , 2008, Proceedings of the National Academy of Sciences.

[84]  Y. Morimoto,et al.  [Prevention of irinotecan hydrochloride-induced diarrhea by oral administration of Lactobacillus casei strain Shirota in rats]. , 2008, Gan to kagaku ryoho. Cancer & chemotherapy.

[85]  J. Tschopp,et al.  Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica , 2008, Science.

[86]  M. Fakih,et al.  Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities. , 2007, Clinical colorectal cancer.

[87]  Teruhiko Yoshida,et al.  Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28 , 2007, Pharmacogenetics and genomics.

[88]  G. Dranitsaris,et al.  Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. , 2007 .

[89]  R. Goldberg,et al.  Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction , 2006, Clinical Cancer Research.

[90]  T. Ikenoue,et al.  Adsorption of irinotecan onto oral adsorbent AST-120 (KremezinTM) for preventing delayed diarrhea , 2006, Cancer Chemotherapy and Pharmacology.

[91]  M. Ratain,et al.  Irinogenetics: what is the right star? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  G. Brandi,et al.  Intestinal microflora and digestive toxicity of irinotecan in mice. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  P. Houghton,et al.  Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  P. Beale,et al.  A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer , 2006, Cancer Chemotherapy and Pharmacology.

[95]  P. Tailliez,et al.  Genetic characterization of the beta-glucuronidase enzyme from a human intestinal bacterium, Ruminococcus gnavus. , 2005, Microbiology.

[96]  S. Clarke,et al.  The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. , 2005, British journal of clinical pharmacology.

[97]  A. Oza,et al.  Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  M. Greenblatt,et al.  A Toll-like Receptor That Prevents Infection by Uropathogenic Bacteria , 2004, Science.

[99]  M. R. Inglis,et al.  Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer , 2003, Journal of gastroenterology and hepatology.

[100]  Kunihiko Kobayashi,et al.  [Chemotherapy-induced diarrhea]. , 2003, Gan to kagaku ryoho. Cancer & chemotherapy.

[101]  A. Di Rienzo,et al.  Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. , 2002, Pharmacogenetics.

[102]  C. Guillemette,et al.  Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). , 2002, Molecular pharmacology.

[103]  H. W. Scheeren,et al.  Beta-glucuronidase-mediated drug release. , 2002, Current pharmaceutical design.

[104]  S. VIdyasagar,et al.  Effects of butyrate on active sodium and chloride transport in rat and rabbit distal colon , 2002, The Journal of physiology.

[105]  Dong-Hyun Kim,et al.  Intestinal bacterial β-glucuronidase activity of patients with colon cancer , 2001 .

[106]  E. Van Cutsem,et al.  Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  J. Verweij,et al.  Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[108]  S. Kudoh,et al.  Prevention of irinotecan (CPT‐11)‐induced diarrhea by oral alkalization combined with control of defecation in cancer patients , 2001, International journal of cancer.

[109]  R. Goldberg,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.

[110]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[111]  S. Kudoh,et al.  pH‐dependent uptake of irinotecan and its active metabolite, SN‐38, by intestinal cells , 1999, International journal of cancer.

[112]  T. Loeffler,et al.  Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[113]  L. Ebringer,et al.  [Successful modification of human intestinal microflora with oral administration of lactic acid bacteria]. , 1999, Bratislavske lekarske listy.

[114]  B. Burchell,et al.  Gilbert's syndrome is a contributory factor in prolonged unconjugated hyperbilirubinemia of the newborn. , 1999, The Journal of pediatrics.

[115]  J. Robert,et al.  Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. , 1998, The Journal of pharmacology and experimental therapeutics.

[116]  P. Mackenzie,et al.  STRUCTURE AND FUNCTION OF URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASES , 1997, Clinical and experimental pharmacology & physiology.

[117]  M. Manns,et al.  Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. , 1997, Molecular pharmacology.

[118]  M Nomura,et al.  Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. , 1996, Cancer research.

[119]  M. Wani,et al.  Camptothecin and taxol: from discovery to clinic. , 1996, Journal of ethnopharmacology.

[120]  D Lindhout,et al.  The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. , 1995, The New England journal of medicine.

[121]  M. Ratain,et al.  Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.

[122]  M. Iigo,et al.  Relationship between Development of Diarrhea and the Concentration of SN‐38, an Active Metabolite of CPT‐11, in the Intestine and the Blood Plasma of Athymic Mice Following Intraperitoneal Administration of CPT‐11 , 1993, Japanese journal of cancer research : Gann.

[123]  T. Furuta,et al.  Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. , 1990, Cancer research.

[124]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[125]  G. Schwartsmann,et al.  Pharmacokinetic and pharmacogenetic markers of irinotecan toxicity. , 2018, Current medicinal chemistry.

[126]  J. Sugatani.  Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase (UGT) 1A1. , 2013, Drug metabolism and pharmacokinetics.

[127]  C. Regnard,et al.  Loperamide. , 2011, Journal of pain and symptom management.

[128]  Marta Mroczyńska,et al.  β-glucuronidase and β-glucosidase Activity of Lactobacillus and Enterococcus Isolated from Human Feces , 2010 .

[129]  I. Kato,et al.  Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen , 2010, Cancer Chemotherapy and Pharmacology.

[130]  J. Bouma,et al.  The regulation of the intestinal mucin MUC2 expression by short chain fatty acids: implications for epithelial protection , 2009 .

[131]  Ji-Youn Han,et al.  Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. , 2009, Lung cancer.

[132]  R. Schilsky,et al.  UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.

[133]  T. Yokokura,et al.  Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats , 2000, Cancer Chemotherapy and Pharmacology.

[134]  M. Ratain,et al.  Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital , 1997, Cancer Chemotherapy and Pharmacology.

[135]  E. Cvitkovic,et al.  Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. , 1996, European journal of cancer.

[136]  P. Chyka,et al.  Multiple-dose activated charcoal and enhancement of systemic drug clearance: summary of studies in animals and human volunteers. , 1995, Journal of toxicology. Clinical toxicology.

[137]  P. Hérait,et al.  CPT-11-induced cholinergic effects in cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  Minmin Li,et al.  Oncotargets and Therapy Dovepress Clinical Significance of Ugt1a1 Gene Polymorphisms on Irinotecan-based Regimens as the Treatment in Metastatic Colorectal Cancer , 2022 .